Table 4.
Cell cycle distribution in MDA-MB-231 cells after EOT treatment.
| Time (h) | 24 | 48 | 72 | |||
|---|---|---|---|---|---|---|
| Treatment | CONT | EOT | CONT | EOT | CONT | EOT |
| Sub-G0/G1 | 1.13 ± 0.20 | 2.46 ± 0.43 | 0.54 ± 0.12 | 3.13 ± 0.33 * | 0.70 ± 0.11 | 7.47 ± 0.55 * |
| G1 | 51.60 ± 2.56 | 60.70 ± 0.90 * | 58.80 ± 0.33 | 60.67 ± 3.26 | 64.83 ± 1.84 | 58.25 ± 2.21 |
| S | 21.55 ± 1.38 | 14.10 ± 2.40 * | 19.80 ± 0.85 | 17.57 ± 1.19 | 15.27 ± 0.78 | 17.75 ± 2.07 |
| G2/M | 25.75 ± 1.13 | 22.75 ± 3.75 | 20.87 ± 1.09 | 18.63 ± 1.15 | 19.20 ± 2.25 | 16.55 ± 1.03 |
Cell cycle distribution in MDA-MB-231 cells after EOT treatment (0.13 µg/mL) was assessed by flow cytometry. Data are expressed as the mean ± SD of three independent experiments. Significant differences between control and EOT-treated cells are shown: * p < 0.05.